2024 Agenda

logologo

*All times are in MST

Sep

Fri 13

2:00PM -3:00PM

Meeting registration

3:00PM -3:10PM

Meeting objectives & introduction to Day 1
Naval Daver

3:10PM -4:10PM

Session 1: Updates on established therapies in AML – Part 1
Chairs: Andrew Wei & Eytan Stein

  • IC+VEN in newly diagnosed fit AML – current status and patient selection: Tapan Kadia
  • Optimizing transplant outcomes in AML and role of maintenance post ASCT: Charles Craddock
  • Role and optimal maintenance strategies in AML patients not going to ASCT: Maximilian Stahl
  • CPX updates & new data: Tara Lin

Panel discussion

4:10PM -5:20PM

Session 2: Translational and lab developments and applications in AML
Chairs: Ravi Majeti & Uma Borate

  • Antigen targets and novel CAR-T strategies: Ravi Majeti
  • Potential for early intervention in CHIP and CCUS: Uma Borate
  • Designing and applying a FLT3 like signature in AML: Adrián Mosquera Orgueira
  • Ancestry-inclusive consideration of AML genomics: Ann-Kathrin Eisfeld
  • Approaches to leverage single-cell sequencing in understanding AML biology and response to therapy: Koichi Takahashi

Panel discussion

5:20PM -5:30PM

Day 1 conclusions

6:30PM -8:00PM

Welcome reception

Sep

Sat 14

8:00AM -8:10AM

Introduction to Day 2
Naval Daver

8:10AM -9:20AM

Session 3: Updates on established therapies in AML – Part 2
Chairs: Naval Daver & Charles Craddock

  • Optimal approach to treatment of secondary/therapy related AML: Jorge Cortes
  • How does IDHm impact frontline treatment of AML: Courtney DiNardo
  • Frontline approaches for FLT3-mutant AML: Naval Daver
  • Current approaches and challenges for relapsed FLT3-mutant AML: Alexander Perl

Panel discussion

9:20AM -10:30AM

Session 4: International trials group
Chairs: Courtney DiNardo & Charles Craddock

  • MDACC: Naval Daver
  • UK & European trials: Charles Craddock
  • French trials: Stéphane de Botton
  • myeloMATCH: Richard Little

Panel discussion

10:30AM -10:50AM

Break

10:50AM -12:00PM

Session 5: Less intensive therapy should be used in all older newly diagnosed AML patients even if fit for intensive chemotherapy
Chairs: Mark Levis & Jessica Altman

Pro: Eunice Wang & Tapan Kadia

Con: Harry Erba & Stéphane de Botton

12:00PM -1:00PM

Lunch

1:00PM -2:00PM

Session 6: New frontiers in MRD for AML clinical practice
Chairs: Stéphane de Botton & Gail Roboz

  • Single-cell sequencing and clinical applicability in detection and therapy of AML: Catherine Smith
  • MRD as a clinical endpoint in clinical trials: Nicholas Short
  • Applying MRD techniques in FLT3-mutated AML – are we able to use MRD as an endpoint?: Christopher Hourigan

Panel discussion

2:00PM -3:10PM

Session 7: BPDCN & MDS/MPN + CMML
Chairs: Marina Konopleva & TBC

  • Updates in diagnosis, pathogenesis, and future directions in BPDCN: Marina Konopleva
  • VEXAS syndrome: Emma Groarke
  • Future targets and trial progress in CMML: Guillermo Montalbán Bravo
  • AP/BP MPN to post-MPN AML: Anand Patel

Panel discussion

3:10PM -3:40PM

Break

3:40PM -4:30PM

Session 8: Transplant and immunotherapies in AML
Chairs: Charles Craddock & Roland Walter

  • Which patients with AML in MRD+ remission should be transplanted?: Roland Walter
  • Early phase CAR-T and NK cell trials for R/R AML and MDS: Nelli Bejanyan
  • NK cell-based therapies in AML: Jeffrey Miller

Panel discussion

4:30PM -5:20PM

Session 9: Special session on regulatory endpoints in AML
Chairs:  Naval Daver & Courtney DiNardo

  • The FDA’s perspective on regulatory endpoints in AML: Kelly Norsworthy
  • A clinical investigator’s perspective on drug development and endpoints: Gail Roboz

Panel discussion

5:20PM -5:30PM

Day 2 conclusions

Faculty dinner

Sep

Sun 15

9:00AM -9:05AM

Introduction to Day 3

9:05AM -10:05AM

Session 10: Menin inhibition
Chairs: Naval Daver & TBC                                                                                              

  • Single-agent menin inhibitors – efficacy, biomarkers and resistance: Eunice Wang
  • Updates on menin inhibitor-based combination in AML: Ghayas Issa
  • Frontline triplets with menin inhibitors in newly diagnosed AML – ready for primetime?: Joshua Zeidner

    Panel discussion
10:05AM -10:45AM

Session 11: Novel targets, combinations and treatments in AML part 1 – new AML therapies and limitations
Chairs: Richard Stone & Marina Konopleva

  • Overcoming resistance to venetoclax-based therapies in AML: Marina Konopleva
  • Promising combination options in AZA/VEN for R/R AML: Thomas Cluzeau
    Panel discussion
10:45AM -11:15AM

Break

11:15AM -12:15PM

Session 12: Novel targets, combinations and treatments in AML part 2
Chairs: Tapan Kadia & Eunice Wang

  • TP53 treatment strategies in AML – how do we crack this nut?: David Sallman
  • Tuspetinib for relapsed or refractory AML: Gabriel Mannis
  • Protein degradation as an emerging therapy in AML/leukemia: Geoffrey Uy

Panel discussion

12:15PM -1:15PM

Session 13: Novel targets, combinations and treatments in AML Part 3
Chairs: Farhad Ravandi & Catherine Smith

  • Optimal use of OGM and RNA-translocation panel in frontline AML: Sanam Loghavi
  • Novel ADCs in AML – how best to incorporate and use them: Farhad Ravandi
  • Leveraging STING for therapeutic benefit in AML: Andrew Wei

 Panel discussion

1:15PM -1:25PM

Day 3 conclusions & closing remarks

Followed by lunch